10x Genomics, Inc.
TXG
$11.16
-$0.545-4.66%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -10.30% | -1.30% | 4.28% | 5.01% | 17.76% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -10.30% | -1.30% | 4.28% | 5.01% | 17.76% |
| Cost of Revenue | -20.72% | -22.12% | 3.55% | 33.14% | 86.70% |
| Gross Profit | -4.17% | 11.37% | 4.63% | -5.26% | -3.28% |
| SG&A Expenses | 5.53% | -0.86% | -6.39% | 1.67% | 16.39% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.34% | -6.71% | -6.05% | 7.59% | 24.35% |
| Operating Income | -47.47% | 22.30% | 31.08% | -14.25% | -78.85% |
| Income Before Tax | -3.82% | 62.46% | 38.98% | -16.41% | -183.94% |
| Income Tax Expenses | -72.47% | 5.88% | -50.33% | 96.34% | 192.79% |
| Earnings from Continuing Operations | -0.16% | 61.55% | 39.28% | -18.13% | -184.36% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -0.16% | 61.55% | 39.28% | -18.13% | -184.36% |
| EBIT | -47.47% | 22.30% | 31.08% | -14.25% | -78.85% |
| EBITDA | -70.65% | 26.12% | 35.27% | -10.32% | -94.57% |
| EPS Basic | 2.35% | 62.51% | 40.99% | -14.40% | -175.27% |
| Normalized Basic EPS | -87.27% | 30.95% | 37.82% | -12.54% | -99.70% |
| EPS Diluted | 2.35% | 62.51% | 40.99% | -14.40% | -175.27% |
| Normalized Diluted EPS | -87.27% | 30.95% | 37.82% | -12.54% | -99.70% |
| Average Basic Shares Outstanding | 2.56% | 2.55% | 2.88% | 3.26% | 3.32% |
| Average Diluted Shares Outstanding | 2.56% | 2.55% | 2.88% | 3.26% | 3.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
